NCT00823797: Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma |
|
|
| Completed | 2 | 45 | US | Bendamustine Hydrochloride, Bendamustin Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Quality-of-Life Assessment, Quality of Life Assessment | University of Washington, National Cancer Institute (NCI), National Comprehensive Cancer Network | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm | 12/15 | 04/17 | | |
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 170 | US | CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine | Cyteir Therapeutics, Inc. | Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer | 07/24 | 12/24 | | |
